摘要
目的探讨树突状细胞(DCs)融合疫苗对黑色素瘤小鼠的免疫保护作用。方法取小鼠骨髓细胞,用粒/巨噬细胞集落刺激因子(GM-CSF)定向诱导分化为骨髓来源的树突状细胞(BMDCs),体外转录血管内皮生长因子受体2(KDR)融合基因的mRNA,将其致敏DCs,按同量不同次免疫小鼠;皮下接种5×105个/只B16细胞建立荷瘤小鼠模型,20 d后未长肿瘤的小鼠再次接种相同剂量的B16细胞,观察小鼠成瘤情况。实验分组:致敏DCs免疫1次组(A组),致敏DCs免疫2次组(B组),致敏DCs免疫3次组(C组),对照组(D组)。结果对照组小鼠一周成瘤率100%,平均存活时间15 d,A组,B组,C组小鼠观察20 d未见肿瘤生长;第二次接种B16细胞后,A组7只中有2只小鼠长出了肿瘤,B组8只中有2只长出了肿瘤,从第一次接种肿瘤细胞开始计算小鼠生存时间,A组平均生存时间50 d;B组平均生存时间72 d;C组未见肿瘤生长。结论树突状细胞KDR融合疫苗对黑色素瘤小鼠具有免疫保护作用。
Objective To investigate the immune protection of dendritic cells （DCs） harboring kinase domain-containing receptor （KDR） fusion gene on mice carrying B16 melanoma. Methods The bone marrow precursor-derived dendritic cells （BMDCs） were induced from bone marrow progenitors of mice by GM-CSF. The KDR fusion gene mRNA was transfected into DCs in vitro. Mice were immunized with the same amount of DCs at 7-day interval and then each mouse was injected with 5×10^5 B16 cells. The mice without tumors were injected with B16 cells again 20 days later. Mice were randomly divided into 4 groups： group A （n = 7）, group B （n = 8）, group C （n = 8） and group D （n = 7）. The mice were immunized with DCs one time in group A, 2 times in group B, 3 times in group C and as controls in group D. Results After one week, all mice in group D had tumors with average survival 15 days. All mice in group A, B and C had no tumors after 20 days later. After the second injection of B16 cells, 2 niice in group A and 2 mice in group B had tumors. The mice in group C had no tumor. The average survival periods were calculated from first injection of B16 cells to the study end. The average survival period of group A was 50 days and that of group B was 72 days. Conclusions The dendritic cells vaccine harboring KDR fusion gene has immune protection against melanoma in mice.
出处
《中国医师杂志》
CAS
2006年第3期306-308,共3页
Journal of Chinese Physician
基金
国家自然科学基金资助项目(30271185)
北京市自然科学基金资助项目(30371627)
